

Kenneth Leong

(603) 7890 8888 (ext 2093)

kenneth.leong@apexsecurities.com.my



Technical Commentary:

Price has rebounded from the low in August and consolidated over a period of one month. Since then, price has formed a rally and the uptrend formation was established. For now, traders may anticipate for a potential flag-formation breakout above RM1.37 to target the next resistances located at **RM1.45-1.50**. Downside wise, support is envisaged at **RM1.32**.

Duopharma Biotech Bhd (7148)		
Board: MAIN	Shariah: Yes	Sector: Pharmaceuticals
Trend: ★★★★★	Momentum: ★★★★★	Strength: ★★★★★
Trading Strategy: Impending flag-formation breakout		
R1: RM1.450 (+5.84%)	R2: RM1.500 (+9.49%)	SL: RM1.320 (-3.65%)



Technical Commentary:

Price has staged a pullback in recent months before bouncing off SMA200. A mild recovery took place and price turned into a consolidation pattern. For now, traders may anticipate for a potential breakout above RM2.03 to target the next resistances located at **RM2.07-2.13**. Downside wise, support is pegged at **RM1.96**.

Pgf Capital Bhd (8117)		
Board: MAIN	Shariah: Yes	Sector: Building Products
Trend: ☆☆☆☆	Momentum: ★★★★★	Strength: ☆☆☆☆
Trading Strategy: Monitor for breakout		
R1: RM2.070 (+3.50%)	R2: RM2.130 (+6.50%)	SL: RM1.960 (-2.00%)

APEX SECURITIES BERHAD – CONTACT LIST

APEX SECURITIES BHD	DEALING TEAM	RESEARCH TEAM
<p>Head Office: 5th Floor Menara UAC, 12, Jalan PJU 7/5, Mutiara Damansara, 47800 Petaling Jaya, Selangor Darul Ehsan, Malaysia</p> <p>General Line: (603) 7890 8899</p> <p>Petaling Jaya Office: 16th Floor, Menara Choy Fook Onn, No.1B Jalan Yong Shook Lin, 46050 Petaling Jaya, Selangor Darul Ehsan, Malaysia</p> <p>General Line: (603) 7620 1118</p>	<p>Head Office: Kong Ming Ming (ext 2002) Lee Chen Ming (ext 2029) Shirley Chang (ext 2026) Ahmad Mujib (ext 2028) Azfar Bin Abdul Aziz (ext 2031) Aizzat Bin Mohd Daud (ext 2030)</p> <p>Institutional Dealing Team: Low Jin Wu (ext 2109)</p> <p>PJ Office: General Line: (603) 7620 1118</p>	<p>Head Office: Kenneth Leong (ext 2093) Steven Chong (ext 2068) Jayden Tan (ext 2069) Chelsea Chew (ext 2070) Tan Sue Wen (ext 2095) Ong Tze Hern (ext 2113)</p>

RESEARCH RECOMMENDATION FRAMEWORK

STOCK RECOMMENDATIONS

BUY: Total returns* are expected to exceed 10% within the next 12 months.
HOLD: Total returns* are expected to be within +10% to – 10% within the next 12 months.
SELL: Total returns* are expected to be below -10% within the next 12 months.
TRADING BUY: Total returns* are expected to exceed 10% within the next 3 months.
TRADING SELL: Total returns* are expected to be below -10% within the next 3 months.
 *Capital gain

SECTOR RECOMMENDATIONS

OVERWEIGHT: The industry defined by the analyst is expected to exceed 10% within the next 12 months.
NEUTRAL: The industry defined by the analyst is expected to be within +10% to – 10% within the next 12 months.
UNDERWEIGHT: The industry defined by the analyst, is expected to be below -10% within the next 12 months.

DISCLAIMER

Disclaimer: The report is for internal and private circulation only and shall not be reproduced either in part or otherwise without the prior written consent of Apex Securities Berhad. The opinions and information contained herein are based on available data believed to be reliable. It is not to be construed as an offer, invitation or solicitation to buy or sell the securities covered by this report.

Opinions, estimates and projections in this report constitute the current judgment of the author. They do not necessarily reflect the opinion of Apex Securities Berhad and are subject to change without notice. Apex Securities Berhad has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate.

All analyst(s) names appear in the front page, whom prepared this report, does not have any interest in the following securities covered in this report.

Apex Securities Berhad does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against Apex Securities Berhad. Apex Securities Berhad may from time to time have an interest in the company mentioned by this report. This report may not be reproduced, copied or circulated without the prior written approval of Apex Securities Berhad.